Bayer has partnered with Google Cloud to expedite the development of AI-powered solutions for radiologists.
The partnership will support healthcare professionals and benefit patients by leveraging Google Cloud's technology, including its generative AI tools.
The companies will address the challenges of creating scalable and compliant AI medical imaging software products, utilising data security measures.
Medical imaging data, which comprises 90% of all healthcare data, is crucial for patient diagnosis.
With billions of medical images scanned annually worldwide, the demand for AI tools to manage and interpret this data efficiently is growing.
Bayer's innovation platform, built on Google Cloud, will provide a cloud-native pipeline to streamline the journey from product idea to launch.
The platform will enable users to analyse and experiment with AI-powered data analysis, access a data ecosystem and utilise intelligent search and data preparation capabilities.
It will also support the development and validation of solutions, including regulatory document generation and leveraging Bayer's medical imaging core lab services for clinical performance evaluation.
After its launch, life science and healthcare companies will be able to deploy AI medical solutions with flexible integration across healthcare systems and monitor field data for insights and continuous improvement.
The platform, incorporating tools such as BigQuery, Vertex AI, Healthcare API and Chronicle, offers new medical imaging tools in the market rapidly and cost-effectively.
The initial version of the platform for extended testing will be available in the EU and the US in 2024.
The new alliance builds on a longstanding partnership between Bayer and Google Cloud which has previously focused on expediting drug discovery and supporting patient diagnosis.
Bayer Radiology president Nelson Ambrogio stated: “Through the collaboration with Google Cloud, our joint efforts will help organisations in the healthcare and life science industry transform the growing amounts of data into valuable and impactful insights, saving radiologists time and helping them optimise their important work for the benefit of patients.”
In February 2024, the US Food and Drug Administration granted breakthrough therapy designation for Bayer’s non-small cell lung cancer (NSCLC) candidate, BAY 2927088.
